On Aug 31st, vice president Dr. Xiaowu Chen from Shanghai Curegene presented an oral report on ESC Congress 2024 titled "Phase I results of both IV and oral administration for CG-0255 ". On the congress, Shanghai Curegene disclosed the progress of the clinical trials for the core pipeline CG-0255. After the presentation on AHA 2023, Shanghai Curegene released the clinical results on world-class academic platform again, disclosing the extensive clinical potentials of the new antiplatelet drug CG-0255.

For more information, please login into the official website of ESC: http://esc365.escardio.org/ESC-Congress/sessions/11547

As a novel antiplatelet drug, CG-0255 is the first prodrug of thiol that was advanced to clinical trial. It is noteworthy that metabolism pathway of CG-0255 is totally different in comparison with the marketed antiplatelet drugs. CG-0255 was metabolized into active form in human by the abundantly expressed carboxylesterase, and its active from was confirmed to be identical to the active form H4 of clopidogrel. Therefore, activation of CG-0255 bypassed the CYP450 enzymes, and in turn, circumvented the problems induced by CYP450 enzymatic metabolism, including clopidogrel resistance, low bioavailability during the biotransformation and extensive drug-drug interaction (DDI). Moreover, CG-0255 satisfied the urgent clinical requirement of fast onset under certain cases, which is unrealizable for clopidogrel. CG-0255 displayed clear dose-efficacy relationship in human for both IV and oral formulations. Phase I results for IV and oral verified the safety, tolerance, good PK and PD profiles of CG-0255. Given the advantages over the marketed antiplatelet drugs, the newcomer CG-0255 is the potential best-in-class antiplatelet drug. Currently, Curegene is pushing the registration clinical trial for CG-0255. Hope it will fulfill the unmet clinical need and bring great benefit to more patients.

（The picture is from the conference site）

About CG-0255
CG-0255 is a revolutionary antiplatelet drug with truly unique and innovative design, it has been developed in two formulations: intravenous and oral. It is currently undergoing clinical development for indications such as acute coronary syndrome, recent myocardial infarction, recent stroke, and peripheral arterial disease to address the shortcomings of existing treatment options, unmet clinical needs, and to provide better antiplatelet solutions for all patients. CG-0255 has rapid onset of action, good safety profile, and shows minimal individual variations, overcoming widely present resistant issue with current treatment. CG-0255 also has little drug-drug interactions. It has the potential to become the best-in-class P2Y12antagonist antiplatelet drug and fully meet the clinical needs in various medication scenarios.